Oxarane-Acrylate System to Double the Clinical Service Life of Restorative Resins

氧烷-丙烯酸酯体系将修复树脂的临床使用寿命提高一倍 摘要：为了开发一种寿命至少是Bis-GMA/TEGDMA的两倍的新型修复系统-- 基复合材料，其不完全固化和对水解和酯酶降解的敏感性必须是 克服困难。为了解决这些问题，我们将开发一种新型的超疏水、抗降解、 基于环氧乙烷/丙烯酸酯互穿网络体系(OASYS，发音为OASIS)的牙科修复剂。 这些基于二氧六环或二丙烯酸酯官能团的含氟氨酯的新型单体可以是 高转化率形成疏水性、耐降解性、韧性和弹性的互穿聚合物 本质上高度交叉的网络(IPN)。从本质上讲，这些特性赋予低残留率 应激性，高耐水解性和酶降解性，以及生物相容性。 我们还将开发一种新型的一步(无底漆)、“智能”抗菌粘合树脂， 无色和颜色稳定的银纳米颗粒(AgNPs)。粘合树脂将含有磷酸基团+ 环氧乙烷和丙烯酸酯两种官能团。环氧乙烷和丙烯酸酯官能团与相应的 IPN树脂基质中的官能团具有比传统甲基丙烯酸酯更强的结合力 系统。磷酸基团将允许粘合树脂润湿蚀刻的矿物表面以及粘合 直接转化为钙-磷酸盐矿物结构中的钙。在边际差距形成的情况下， 原位生成的AgNPs将释放银离子并创造抗菌环境，从而进一步减少 复发龋齿的发生率。 提出了五个具体目标：1.确定使用环氧乙烷的效果，增加疏水性，以及 IPN对树脂的力学性能、物理性能和体外生物相容性的影响。越有希望 组合物将与增强填充剂结合并用于目标2。为了确定使用4- 磷-NPG氧烷(4POA)键合体系及原位生成银纳米粒子(AgNP) 粘接树脂的力学性能、物理性能及体外生物相容性和抗菌性能的研究 活性，以及与环氧乙烷/丙烯酸酯互穿网络复合材料的结合强度。两个最好的- 出于后续目的，将选择性能良好的复合材料。3.为确定使用环氧乙烷的效果， 疏水性增强，IPN对树脂耐口腔生化环境。两个最好的- 在AIM 2中选择的表演团体将在暴露于酸性、碱性和酸性环境后进行疲劳和磨损测试 在含有酯酶的环境中放置90天。4.为了确定使用环氧乙烷的效果，增加了 疏水性，以及对树脂耐细菌降解的IPN。两个表现最好的组合来自 目标2将在人工口腔细菌生物膜模型中进行测试。5.测定其体内生物相容性 OASYS。性能最好的OASYS将在三个体内生物兼容性模型中进行测试：延迟型 过敏、口腔粘膜刺激、牙髓和牙本质反应试验。 1

Oxarane-Acrylate System to Double the Clinical Service Life of Restorative Resins Abstract: In order to develop a novel restorative system with at least twice the lifetime of Bis-GMA/TEGDMA- based composites, their incomplete cure and susceptibility to hydrolysis and esterase degradation must be overcome. To address these problems, we will develop a novel superhydrophobic, degradation-resistant, dental restorative based on an Oxirane/Acrylate interpenetrating network System (OASys, pronounced Oasis). These novel monomers based on fluoridated urethanes with either dioxirane or diacrylate functionality can be highly converted to form a hydrophobic, degradation-resistant, tough and resilient interpenetrating polymer network (IPN) that is inherently highly crosslinked. By their nature, these characteristics impart low residual stresses, high resistance to hydrolytic and enzymatic degradation, and biocompatibility. We will also develop a novel one-step (primer-less), "smart," antimicrobial bonding resin with in situ-generated, colorless and color stable, silver nanoparticles (AgNPs). The bonding resin will contain a phosphate group plus both oxirane and acrylate functionalities. The oxirane and acrylate functionalities bond to the corresponding functionalities in the IPN resin matrix for potentially a much stronger bond than the conventional methacrylate system. The phosphate group will allow the bonding resin to wet etched mineral surfaces as well as bond directly to calcium in Ca-phosphate mineral structures. In the event of marginal gap formation, the "smart" in situ-generated AgNPs will release Ag+ ions and create an antibacterial environment, thereby further reducing the incidence of recurrent caries. Five specific aims are proposed: 1. To determine the effect of using oxiranes, increased hydrophobicity, and IPNs on resin mechanical properties, physical properties and in vitro biocompatibility. The more promising compositions will be combined with reinforcing filler and used for Aim 2. 2. To determine the effect of using a 4- Phospho-NPG GA oxirane (4POA)-based bonding system and in situ-generated silver nanoparticles (AgNP) on bonding resin mechanical properties, physical properties, and in vitro biocompatibility and antibacterial activity, as well as on bond strength to oxirane/acrylate interpenetrating network composites.. The two best- performing composites will be chosen for subsequent aims. 3. To determine the effect of using oxiranes, increased hydrophobicity, and IPNs on resin resistance to the oral biochemical environment. The two best- performing groups chosen in Aim 2 will be fatigue- and wear-tested after exposure to acidic, basic and esterase-containing environments for 90 days. 4. To determine the effect of using oxiranes, increased hydrophobicity, and IPNs on resin resistance to bacterial degradation. The two best-performing groups from Aim 2 will be tested in an artificial mouth bacterial biofilm model. 5. To determine the in vivo biocompatibility of the OASys. The best performing OASys will be tested in three in vivo biocompatibility models: delayed-type hypersensitivity, oral mucosa irritation, and pulp and dentin response tests. 1